ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

A Curative Strategy for High-Risk Smoldering Multiple Myeloma?

In a phase II trial of patients with previously untreated smoldering multiple myeloma (SMM), the combination of carfilzomib, lenalidomide, and dexamethasone, followed by autologous...

Final Analysis of IFM2009 Trial Confirms Predictive Value of Minimal Residual Disease in Myeloma

Because survival for patients with multiple myeloma (MM) has significantly improved within the past decade, complete response (CR) rates may no longer be a...

Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory...

According to final results from the phase III ASPIRE study assessing patients with relapsed/refractory multiple myeloma (MM), adding the proteasome inhibitor carfilzomib to a...

Doubling Down on Double Transplant for Myeloma: Updated Results from EMN02/H095

More than a year ago, at the 2016 ASH Annual Meeting, Michele Cavo, MD, from the Serágnoli Institute of Hematology at Bologna University School...

BCMA Antibody Drug Conjugate Active in Patients With Heavily Pretreated Myeloma

In a phase I study presented at the 2017 ASH Annual Meeting, 60 percent of patients with heavily-pretreated multiple myeloma (MM) responded to treatment...

Early-Phase Study Finds Venetoclax Plus Obinutuzumab Safe and Effective in Patients with Untreated CLL

Venetoclax – a highly selective, potent BCL2 inhibitor – demonstrated significant anti-tumor activity in patients with chronic lymphocytic leukemia (CLL), both as monotherapy and...

For Patients With Plasma Cell Disorders, Are Two Flu Vaccines Better Than One?

Patients with plasma cell disorders (PCDs) such as multiple myeloma (MM) have compromised immunity, and potent anti-cancer treatments further deplete immunity, making them highly...

Brentuximab Vedotin Plus R-CHP a Frontline Treatment Option for Patients with NHL Subtypes

The CD30-directed immunoconjugate brentuximab vedotin has demonstrated efficacy in Hodgkin lymphoma (HL) and other T-cell lymphomas. According to research presented at the 2017 ASH...

Addition of Rituximab to High-Dose Chemotherapy Does Not Improve Response in Patients With Central...

According to results of an international, randomized, phase III trial, combining rituximab with high-dose, methotrexate-based chemotherapy did not improve response rates or survival for...

Daratumumab Shows Efficacy in Previously Treated Systemic Light-Chain Amyloidosis

Daratumumab, an anti-CD38 monoclonal antibody indicated for the treatment of patients with multiple myeloma (MM), has also shown efficacy in patients with systemic light-chain...
Advertisement

Current Issue

July 2018 Bonus Mid-Year Edition

This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.